echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cell Death Dis: The expression level of BH3-only protein determines the response of hepatocellular carcinoma patients to sorafenib-based drug combination therapy

    Cell Death Dis: The expression level of BH3-only protein determines the response of hepatocellular carcinoma patients to sorafenib-based drug combination therapy

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hepatocellular carcinoma (HCC) is a serious global health problem.


    Hepatocellular carcinoma (HCC) is a serious global health problem.


    Recently, a combination therapy of atezolizumab (anti-PDL1) and bevacizumab (anti-VEGF) , an immune checkpoint inhibitor, has been approved as a first-line therapy for advanced HCC


    immunity




    Sorafenib and TRAIL-induced cell death

    Sorafenib and TRAIL-induced cell death

    The researchers found that these two drugs can enhance the cell death effect induced by sorafenib, but this depends on the specific BH3-only protein




    Sorafenib reduces the proliferation of Huh7 cells

    Sorafenib reduces the proliferation of Huh7 cells

    All in all, the results of this study show that the expression of BH3-only protein determines the therapeutic response of HCC to different sorafenib drug combinations


    The results of this study indicate that the expression of BH3-only protein determines the therapeutic response of HCC to different sorafenib drug combinations



    BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.